Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.
Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus.Pfizer Inc.'s top-selling COVID-19 vaccine and treatment have left the New York City drugmaker flush with cash to spend on an acquisition spree. The vaccine and treatment brought in more than $16 billion combined just in the recently completed second quarter.
Aside from Oxbryta, Global Blood Therapeutics also is developing some other treatments for sickle cell disease. Sickle cell disease is an inherited blood disorder that can lead to bouts of acute pain and organ damage. It occurs particularly among people of African descent.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer in talks on $5 billion acquisition: mediaAmerican drugmaker Pfizer is close to a deal to purchase Global Blood Therapeutics, which manufactures a recently approved drug against sickle-cell anemia, for $5 billion, the Wall Street Journal has reported.
Baca lebih lajut »
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJPfizer Inc. undefined has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal...
Baca lebih lajut »
Pfizer in talks on $5 billion acquisition: mediaAmerican drugmaker Pfizer is close to a deal to purchase Global Blood Therapeutics, which manufactures a recently approved drug against sickle-cell anemia, for $5 billion, the Wall Street Journal has reported.
Baca lebih lajut »
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJPfizer Inc. undefined has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal...
Baca lebih lajut »
Elon Musk says Twitter deal could go forward once user data confirmedEven as countersuits are served regarding Elon Musk's wanting to back out of deal to buy Twitter, the Tesla CEO says the deal could still go through.
Baca lebih lajut »